1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Female Sexual Dysfunction - Pipeline Review, H1 2016

Female Sexual Dysfunction - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 81 pages

Female Sexual Dysfunction - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Female Sexual Dysfunction - Pipeline Review, H1 2016’, provides an overview of the Female Sexual Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction
- The report reviews pipeline therapeutics for Female Sexual Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Female Sexual Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Female Sexual Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Female Sexual Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Female Sexual Dysfunction - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2

Introduction 7
Global Markets Direct Report Coverage 7
Female Sexual Dysfunction Overview 8
Therapeutics Development 9
Pipeline Products for Female Sexual Dysfunction - Overview 9
Pipeline Products for Female Sexual Dysfunction - Comparative Analysis 10
Female Sexual Dysfunction - Therapeutics under Development by Companies 11
Female Sexual Dysfunction - Therapeutics under Investigation by Universities/Institutes 12
Female Sexual Dysfunction - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Female Sexual Dysfunction - Products under Development by Companies 16
Female Sexual Dysfunction - Products under Investigation by Universities/Institutes 17
Female Sexual Dysfunction - Companies Involved in Therapeutics Development 18
Apricus Biosciences, Inc. 18
Emotional Brain BV 19
EndoCeutics, Inc. 20
M et P Pharma AG 21
Palatin Technologies, Inc. 22
Re-Pharm Limited 23
TherapeuticsMD, Inc. 24
Valeant Pharmaceuticals International, Inc. 25
Female Sexual Dysfunction - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(sildenafil citrate + testosterone) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
alprostadil - Drug Profile 38
Product Description 38
Mechanism Of Action 38
RandD Progress 38
bremelanotide - Drug Profile 45
Product Description 45
Mechanism Of Action 45
RandD Progress 45
prasterone - Drug Profile 50
Product Description 50
Mechanism Of Action 50
RandD Progress 50
S1B-3006 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
RandD Progress 52
S1B-307 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
RandD Progress 53
SIP-104 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
RandD Progress 54
Small Molecule for Sexual Dysfunction - Drug Profile 56
Product Description 56
Mechanism Of Action 56
RandD Progress 56
Small Molecules to Agonize Dopamine for Sexual Dysfunction - Drug Profile 57
Product Description 57
Mechanism Of Action 57
RandD Progress 57
SPT-201 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
RandD Progress 58
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 59
Product Description 59
Mechanism Of Action 59
RandD Progress 59
TBS-2 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
RandD Progress 60
TX-004HR - Drug Profile 64
Product Description 64
Mechanism Of Action 64
RandD Progress 64
Female Sexual Dysfunction - Dormant Projects 67
Female Sexual Dysfunction - Discontinued Products 70
Female Sexual Dysfunction - Product Development Milestones 71
Featured News and Press Releases 71
May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial 71
Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor and Medical Conferences 71
Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 72
Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 72
Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 73
Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 73
Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 74
Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR 75
Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference 76
Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting 76
Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder 76
Aug 19, 2015: Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction 77
Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction 78
Jun 11, 2015: Trimel Confirms Next FDA Meeting on TEFINA 79
Jun 09, 2015: TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables
Number of Products under Development for Female Sexual Dysfunction, H1 2016 9
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Female Sexual Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2016 18
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2016 19
Female Sexual Dysfunction - Pipeline by EndoCeutics, Inc., H1 2016 20
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2016 21
Female Sexual Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2016 22
Female Sexual Dysfunction - Pipeline by Re-Pharm Limited, H1 2016 23
Female Sexual Dysfunction - Pipeline by TherapeuticsMD, Inc., H1 2016 24
Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Female Sexual Dysfunction - Dormant Projects, H1 2016 67
Female Sexual Dysfunction - Dormant Projects (Contd..1), H1 2016 68
Female Sexual Dysfunction - Dormant Projects (Contd..2), H1 2016 69
Female Sexual Dysfunction - Discontinued Products, H1 2016 70

List of Figures
Number of Products under Development for Female Sexual Dysfunction, H1 2016 9
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Top 10 Targets, H1 2016 28
Number of Products by Stage and Top 10 Targets, H1 2016 28
Number of Products by Top 10 Mechanism of Actions, H1 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34

Companies Mentioned
Apricus Biosciences, Inc.
Emotional Brain BV
EndoCeutics, Inc.
M et P Pharma AG
Palatin Technologies, Inc.
Re-Pharm Limited
TherapeuticsMD, Inc.
Valeant Pharmaceuticals International, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Erectile Dysfunction  - Market Insights, Epidemiology and Market Forecast-2023

Erectile Dysfunction  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Erectile Dysfunction - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Global Erectile Dysfunction Drugs Market Report 2016

Global Erectile Dysfunction Drugs Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Erectile Dysfunction Drugs Report is a professional and in-depth research report on the world's major regional market conditions of the Erectile Dysfunction Drugs industry, focusing on the ...

Erectile Dysfunction  - Epidemiology Forecast To 2023

Erectile Dysfunction  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Erectile Dysfunction  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Erectile Dysfunction  in seven major markets (US, France, Germany, Italy, Spain, ...


Download Unlimited Documents from Trusted Public Sources

Opioid and Dysfunction Drug Market in Canada

  • October 2016
    71 pages
  • Opioid  

    Dysfunction Dru...  

  • Canada  

View report >

Dysfunction Drug Market and Genitourinary System Disease Statistics in the UK

  • August 2016
    15 pages
  • Dysfunction Dru...  

    Genitourinary S...  

    Dermatological ...  

  • United Kingdom  

View report >

Hormone and Therapy Market in the US

  • July 2016
    8 pages
  • Hormone  

    Therapy  

    Prostate Cancer  

  • United States  

View report >

Therapy Market In The Us

11 months ago

Therapy Market In Israel

11 months ago

Related Market Segments :

Dysfunction Drug

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.